Immunohistochemical expression of podoplanin in so-called hard α-keratin-expressing tumors, including calcifying cystic odontogenic tumor, craniopharyngioma, and pilomatrixoma.
Podoplanin, a transmembrane sialomucin-like glycoprotein, is a specific marker of lymphatic vessels, and its expression is also considered to be associated with tumor invasion and tooth development. In this study, we examined the expression of podoplanin in calcifying cystic odontogenic tumor (CCOT) in comparison with that in other so-called hard α-keratin-expressing tumors such as craniopharyngioma (CP) and pilomatrixoma (PM). Immunohistochemical staining for podoplanin was carried out using surgical specimens of 15 CCOTs of the jaw, 19 CPs of the pituitary gland, and 15 PMs of the skin. Positivity for hard α-keratin was evident in ghost, shadow and transitional cells in all of these tumors (100%). The podoplanin expression in CCOTs was evident in the periphery of ameloblastoma-like epithelium (86.6%) and the epithelial cells adjacent to ghost cells (60%). On the other hand, in adamantinomatous-type CPs, podoplanin expression was observed in epithelial components corresponding to the stratum intermedium (100%), but not in the periphery of ameloblastoma-like epithelium (0%). In squamous-type CPs podoplanin was expressed in basal cells (100%), but all of the PMs were podoplanin-negative (0%). In the periphery of the ameloblastoma-like epithelium or basophilic cell layer, podoplanin was expressed more strongly in CCOTs than in CPs or PMs. These findings suggest that the expression of podoplanin in CCOTs may reflect rapid turnover of cytoskeletal filaments and local invasiveness.
Division of Pathology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Japan. k-kikuchi@dent.meikai.ac.jp
Kentaro
K
Kikuchi
Shigeru
S
Ito
Harumi
H
Inoue
Patricia
P
González-Alva
Yuji
Y
Miyazaki
Hideaki
H
Sakashita
Atsuo
A
Yoshino
Yoichi
Y
Katayama
Tadashi
T
Terui
Fumio
F
Ide
Kaoru
K
Kusama
D001491:Basophils / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis; D003397:Craniopharyngioma / Q000473:pathology*; D003599:Cytoskeleton / Q000473:pathology; D004847:Epithelial Cells / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007573:Jaw Neoplasms / Q000473:pathology; D007633:Keratins / Q000032:analysis*; D008562:Membrane Glycoproteins / Q000032:analysis*; D009361:Neoplasm Invasiveness; D009808:Odontogenic Tumors / Q000473:pathology*; D009810:Odontoma / Q000473:pathology; D018296:Pilomatrixoma / Q000473:pathology*; D010911:Pituitary Neoplasms / Q000473:pathology; D012878:Skin Neoplasms / Q000473:pathology; D000098853:Podoplanin
D014408:Biomarkers, Tumor; D007633:Keratins; D008562:Membrane Glycoproteins; C117468:PDPN protein, human; D000098853:Podoplanin